Proqr Therapeutics Bv Stock Today
| PRQR Stock | USD 3.67 0.23 6.69% |
Performance8 of 100
| Odds Of DistressLess than 10
|
ProQR Therapeutics is selling at 3.67 as of the 29th of November 2024; that is 6.69 percent up since the beginning of the trading day. The stock's lowest day price was 3.41. ProQR Therapeutics has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for ProQR Therapeutics BV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of September 2014 | Category Healthcare | Classification Health Care |
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. The company has 105.91 M outstanding shares of which 413.76 K shares are at this time shorted by private and institutional investors with about 0.12 trading days to cover. More on ProQR Therapeutics BV
Moving together with ProQR Stock
| 0.76 | ESPR | Esperion Therapeutics | PairCorr |
| 0.76 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.75 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against ProQR Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ProQR Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Daniel Boer | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsProQR Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ProQR Therapeutics' financial leverage. It provides some insight into what part of ProQR Therapeutics' total assets is financed by creditors.
| |||||
ProQR Therapeutics BV (PRQR) is traded on NASDAQ Exchange in USA. It is located in Zernikedreef 9, Leiden, Netherlands, 2333 CK and employs 156 people. ProQR Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 388.68 M. ProQR Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 105.91 M outstanding shares of which 413.76 K shares are at this time shorted by private and institutional investors with about 0.12 trading days to cover.
ProQR Therapeutics BV currently holds about 156.4 M in cash with 21.55 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19.
Check ProQR Therapeutics Probability Of Bankruptcy
Ownership AllocationProQR Therapeutics owns a total of 105.91 Million outstanding shares. ProQR Therapeutics holds 14.49 pct. of its outstanding shares held by insiders and 24.9 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check ProQR Ownership Details
ProQR Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 155.9 K | |
| Franklin Street Advisors Inc. | 2024-09-30 | 150 K | |
| Millennium Management Llc | 2024-06-30 | 148.4 K | |
| Two Sigma Advisers, Llc | 2024-06-30 | 131.5 K | |
| Boothbay Fund Management, Llc | 2024-09-30 | 106.7 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 96.1 K | |
| Citadel Advisors Llc | 2024-09-30 | 87 K | |
| Squarepoint Ops Llc | 2024-06-30 | 84.7 K | |
| Bank Of America Corp | 2024-06-30 | 73.2 K | |
| Privium Fund Management B.v. | 2024-09-30 | 5.6 M | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 3.6 M |
ProQR Therapeutics Historical Income Statement
ProQR Stock Against Markets
ProQR Therapeutics Corporate Management
| Aniz MD | Chief Officer | Profile | |
| Domenico Valerio | Founder Board | Profile | |
| Sarah Kiely | Vice Communications | Profile | |
| Rene Beukema | Chief Corporate Devel. Officer, General Counsel, Corporate Secretary and Member of Management Board | Profile | |
| Sheila Sponselee | VP Operations | Profile | |
| Gerard Platenburg | Chief Innovation Officer | Profile |
Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.